[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369497-105":59,"doc-detail-369497-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","microbiota-as-diagnostic-biomarkers-advancing-early-cancer-detection-and-personalized-therapeutic-approaches-through-microbiome-profiling","Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling","","Microbiota is presented as a therapeutic modulator and diagnostic biomarker platform in oncology, emphasizing host–microbe interactions in colorectal and breast cancer. Microbial signatures such as Bacteroides fragilis and Fusobacterium nucleatum are discussed for their roles in carcinogenesis and tumor progression, alongside microbiome influence on immunotherapy and chemotherapy effectiveness, including potential side-effect reduction. The review also evaluates emerging precision strategies—dietary modification and fecal microbiota transplantation—while addressing ongoing challenges such as inter-individual variability, lack of standardization, and biomarker validation gaps, proposing integration with liquid biopsies and machine learning for improved early detection and management.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microbiota-as-diagnostic-biomarkers-advancing-early-cancer-detection-and-personalized-therapeutic-approaches-through-microbiome-profiling/369497/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microbiota-as-diagnostic-biomarkers-advancing-early-cancer-detection-and-personalized-therapeutic-approaches-through-microbiome-profiling/369497.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which cancers are重点讨论 in the review when discussing microbiota biomarkers?","Question",{"text":113,"@type":114},"The review specifically focuses on colorectal cancer (CRC), breast cancer, lung cancer, pancreatic cancer, and prostate cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How can microbiota improve cancer diagnosis and treatment outcomes?",{"text":118,"@type":114},"Microbiome profiling may enable early, noninvasive diagnostic methods using microbial signatures, and microbiota can also affect responses to immunotherapy and chemotherapy, improving outcomes and potentially reducing side effects.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges limit microbiota-based biomarker implementation?",{"text":122,"@type":114},"Key issues include individual variations in microbial composition, lack of standardized procedures, and the need for reliable, validated biomarkers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369497,1790290360,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 08 May 2025  \nDOI 10.3389/fimmu.2025.1559480  \nOPEN ACCESS  \nEDITED BY  \nNar Singh Chauhan,  \nMaharshi Dayanand University, India  \nREVIEWED BY  \nMonika Yadav,  \nSanjay Ghodawat University, India Asiya Nazir,  \nAbu Dhabi University, United Arab Emirates  \n*CORRESPONDENCE  \nValentyn Oksenych  \n [valentyn.oksenych@uib. no](valentyn.oksenych@uib. no)[ ](valentyn.oksenych@uib. no)Hamed Tahmasebi  \n [h.tahmasebi87@yahoo.com](h.tahmasebi87@yahoo.com)  \nRECEIVED 12 January 2025  \nACCEPTED 16 April 2025  \nPUBLISHED 08 May 2025  \nCITATION  \nEslami M, Naderian R, Bahar A, Babaeizad A, Rezanavaz Gheshlagh S, Oksenych V and Tahmasebi H (2025) Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome proﬁling.  \nFront. Immunol. 16:1559480 .  \ndoi: 10.3389/fimmu.2025.1559480  \nCOPYRIGHT  \n© 2025 Eslami, Naderian, Bahar, Babaeizad, Rezanavaz Gheshlagh, Oksenych and Tahmasebi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMicrobiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome proﬁling  \nMajid Eslami 1, Ramtin Naderian 2, Aisa Bahar 3, Ali Babaeizad 4, Solaleh Rezanavaz Gheshlagh 4, Valentyn Oksenych 5* and Hamed Tahmasebi 6*  \n1Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran, 2Clinical Research Development Unit, Kowsar Educational, Research and Therapeutic Hospital, Semnan University of Medical Sciences, Semnan, Iran, 3 Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, 4Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran, 5 Faculty of Medicine, University of Bergen, Bergen, Norway, 6School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran  \nThe important function of microbiota as therapeutic modulators and diagnostic biomarkers in cancer has been shown by recent developments in microbiome research. The intricate interplay between the gut microbiota and the development of cancer, especially in colorectal and breast cancers, emphasizes how microbial proﬁling may be used for precision treatment and early diagnosis. Important microbial signatures, including Bacteroides fragilis and Fusobacterium nucleatum, have been linked to the development and progression of cancer, providing important information on the processes behind carcinogenesis. Additionally, the inﬂuence of microbiota on the effectiveness of treatments such as immunotherapy and chemotherapy highlights its dual function in improving treatment outcomes and reducing side effects. To optimize treatment results, strategies including dietary changes and fecal microbiota transplantation (FMT) are being investigated. Despite these developments, there are still issues, such as individual variations in microbial composition, a lack of standardized procedures, and the requirement for reliable biomarkers . Integrating microbiome-based diagnostics with conventional approaches, such as liquid biopsies and machine learning algorithms, could revolutionize cancer detection and management. This review provides an overview of the current understanding of the host–microbe immunological axis and discusses emerging therapeutic strategies centered on microbiota modulation to support human health. Further research is essential to overcome existing challenges and fully realize the promise of microbiotadriven innovations in oncology.  \nKEYWORDS  \nbiomarkers, cancer, microbiota, microbiome proﬁling, personalized medicine  \nFro","cbCaihSr1o2TIy7i","https://ap.wps.com/l/cbCaihSr1o2TIy7i","pdf",2192080,18,"English","# 1 Current research on microbiota in early cancer detection\n## Host–microbe tolerance and gut communication\n## Microbiota biomarkers in colorectal, breast, lung, pancreatic, and prostate cancer","[{\"question\":\"Which cancers are重点讨论 in the review when discussing microbiota biomarkers?\",\"answer\":\"The review specifically focuses on colorectal cancer (CRC), breast cancer, lung cancer, pancreatic cancer, and prostate cancer.\"},{\"question\":\"How can microbiota improve cancer diagnosis and treatment outcomes?\",\"answer\":\"Microbiome profiling may enable early, noninvasive diagnostic methods using microbial signatures, and microbiota can also affect responses to immunotherapy and chemotherapy, improving outcomes and potentially reducing side effects.\"},{\"question\":\"What challenges limit microbiota-based biomarker implementation?\",\"answer\":\"Key issues include individual variations in microbial composition, lack of standardized procedures, and the need for reliable, validated biomarkers.\"}]","Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling | PDF",1790183074,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7a9508391f923a4e527bcda33be51d0.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2627896a1ddd05b289ddd61b1dd676cc.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c930c53757a6a0fe8f6bacbfbe018572.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8576d6127a1a08af65ed5a4df610287a.webp",980,1385]